<DOC>
	<DOCNO>NCT00446290</DOCNO>
	<brief_summary>Considering synergism docetaxel ( D ) , capecitabine ( X ) , oxaliplatin ( O ) favourable toxicity profile oxaliplatin cisplatin , expect combination docetaxel , capecitabine , oxaliplatin ( DXO ) effective regimen feasible advanced gastric cancer . DXO regimen also easily administer out-patient setting . However , far , DXO combination try advanced gastric cancer . The investigator determine maximum tolerate dose DXO regimen phase I study .</brief_summary>
	<brief_title>Study Docetaxel , Capecitabine Oxaliplatin Advanced Stomach Cancer</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>Histologically confirm unresectable metastatic advance gastric adenocarcinoma Completion adjuvant chemotherapy 6 month study , previous chemotherapy ( But , patient receive docetaxel , capecitabine , oxaliplatin adjuvant chemotherapy exclude . ) Age 18 70 year old Eastern Cooperative Oncology Group performance status 0~2 Adequate bone marrow function : white blood cell count &gt; 4,000/µL , absolute neutrophil count &gt; 2,000/µL , platelet &gt; 100,000/µL Adequate renal function : creatinine &lt; 1 x upper normal limit ( UNL ) creatinine clearance 60ml/min Adequate hepatic function : bilirubin &lt; 1.5 x UNL , aspartate aminotransferase ( AST ) /alanine aminotransferase ( ALT ) level &lt; 2.5 x UNL , alkaline phosphatase &lt; 5 x UNL ( except case bone metastasis without liver disease ) Given write informed consent prior studyspecific screening procedure , understand patient right withdraw study time , without prejudice Contraindication drug contain chemotherapy regimen Other tumor type adenocarcinoma Presence history central nervous system ( CNS ) metastasis Gastric outlet bowel obstruction Evidence serious gastrointestinal bleeding Peripheral neuropathy &gt; grade 1 History significant neurologic psychiatric disorder History another malignancy within last five year except cure basal cell carcinoma skin cure carcinoma insitu uterine cervix Pregnant lactate woman , woman childbearing potential employ adequate contraception . Postmenopausal woman must amenorrheic least 12 month consider nonchildbearing potential Sexually active male female ( childbearing potential ) unwilling practice conception study Clinically significant cardiac disease ( e.g . severe noncompensated hypertension , noncompensated heart failure , dilate cardiomyopathy , coronary heart disease ST segment depression electrocardiogram ) myocardial infarction within last 6 month Serious pulmonary conditions/illness ( e.g . chronic lung disease hypoxemia ) Serious metabolic disease severe noncompensated diabetes mellitus Serious uncontrolled intercurrent infection , serious uncontrolled concomitant disease Positive serology human immunodeficiency virus ( HIV )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>To determine maximal tolerate dose DXO regimen</keyword>
</DOC>